| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04450654 Details | 2022-10-24 Interventional | 2 | 0 | Immunoglobulins… Muscular Diseas… Immune-Mediated… | No Participants Enrolled - | |||
| NCT05028946 2021-002698-24 Details | 2022-10-20 Interventional | 1 | 0 | Muromonab-CD3 Crohn Disease Crohn's Disease | For business reasons - | |||
| NCT04454567 Details | 2022-10-20 Interventional | 2 | 2 | Reverse Transcr… Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Chronic Hepatit… | Study stopped due to a change in the Sponsor's overall development strategy from treatment of
chronic disease to finite, curative treatments, and is based partially on the advice and
feedback from experts and regulators. Study ABI-H0731-205 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies. At the time of early termination, only 2 participants were enrolled, both of which discontinued their assigned study treatment early due to the study being terminated early by the Sponsor. As a result, the primary outcome of number of participants with HBV DNA | |||
| NCT03693846 Details | 2022-10-20 Interventional | 2 | 11 | Ipilimumab Nivolumab Adenocarcinoma Adenocarcinoma,… Appendiceal Neo… Cystadenocarcin… Mucinous Adenoc… Mucinous Adenoc… | Terminated due to slow enrollment and lack of efficacy Early termination leading to small numbers of subjects analyzed. | |||
| NCT02303405 Details | 2022-10-20 Interventional | 2 | 22 | Hydroxychloroqu… Pioglitazone Diabetes Mellit… Diabetes Mellit… Hyperglycemia Diabetes Mellit… | Investigator decision Small sample size, Unblinded | |||
| NCT02055963 Details | 2022-10-20 Interventional | 2 | 30 | Minocycline Head and Neck N… Head And Neck C… | Early termination due to the protocol lack of progress in improving accrual rate Early termination due to the protocol lack of progress in improving accrual rate. | |||
| NCT03249844 2017-002247-15 Details | 2022-10-19 Interventional | 3 | 0 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Ischemic Stroke Stroke Arterial Ischem… | discontinuation of the trial - | |||
| NCT02432378 Details | 2022-10-19 Interventional | 1/2 | - | Celecoxib Cisplatin Vaccines Carcinoma, Ovar… Neoplasms Ovarian Neoplas… Cancer of Ovary Cancer of the O… Neoplasms, Ovar… Ovarian Cancer Ovary Cancer Ovary Neoplasms | - - | |||
| NCT01855607 Details | 2022-10-19 Interventional | 2 | 11 | Menthol Peripheral Nerv… Breast Cancer Colon Cancer Neuropathy | Lack of feasibility - | |||
| NCT05231603 Details | 2022-10-18 Interventional | 3 | 50 | Ivermectin COVID-19 | Poor response - | |||
| NCT04088591 Details | 2022-10-18 Interventional | 3 | 0 | Ascorbic Acid Sepsis Toxemia | Recent studies suggest an increase in mortality due to high-does Vitamin C - | |||
| NCT05239910 Details | 2022-10-17 Interventional | 2 | 0 | Tenalisib Lymphoma Lymphoma, T-Cel… Lymphoma, T-Cel… Peripheral T Ce… | Change in development plan - | |||
| NCT05130086 Details | 2022-10-17 Interventional | 2 | 0 | Islatravir Acquired Immuno… HIV Infections Infections Human Immunodef… | Business Reasons - | |||
| NCT04811404 Details | 2022-10-14 Interventional | 4 | 0 | Eicosapentaenoi… Bipolar Disorde… | Reassessment of rationale for study - | |||
| NCT03612466 Details | 2022-10-14 Interventional | 1 | 0 | Calcium Calcium Carbona… Plerixafor Osteosarcoma Bone Metastases | Study withdrawn before any participants could be enrolled. Issues being able to effectively
recruit participants into the study. - | |||
| NCT03359161 Details | 2022-10-13 Interventional | 2/3 | 9 | Furosemide Heart Failure | Development of first generation device discontinued. - | |||
| NCT01464593 Details | 2022-10-13 Interventional | 2 | 2 | Doxorubicin Liposomal doxor… Colonic Neoplas… Neoplasm Metast… Colon Cancer Li… | trial design contingent on RFA optimization - | |||
| NCT02716805 Details | 2022-10-12 Interventional | 1 | 6 | Durvalumab Melphalan Tremelimumab Multiple Myelom… | FDA placed on partial hold due to additional data Early termination due to safety signals in other studies investigating combination regimens comprising similar drugs. Because only 6 subjects were enrolled, no final statistical analysis plan was issued and no formal data analyses were performed. | |||
| NCT04022876 Details | 2022-10-10 Interventional | 1 | 35 | Carboplatin Pemetrexed Topotecan Lung Neoplasms Small Cell Lung… Non Small Cell … Small-cell Lung… | With a favorable safety profile the difference between treatment groups for the primary
composite endpoint was not sufficient to generate statistically significant results with the
targeted sample size - | |||
| NCT03933865 Details | 2022-10-10 Interventional | 1 | 1 | Hydromorphone Ketamine Acute Pain Opioid-Related … Opioid-use Diso… Pain, Acute | The COVID-19 pandemic and recruitment difficulties prompted the investigators to terminate
study early. - |